Integrative disease-drug-trial platform for Parkinson’s disease

Despite the wide research on Parkinson’s disease (PD), current knowledge on how to link pathophysiological changes and clinical symptoms is still minimal. We are developing an integrative disease-drug-trial platform using different analysis approaches that serves as a quantitative link between (potential) biomarkers of disease progression and clinical scores. This platform could help as a tool during drug development to test/confirm hypothesis and for strategic decision making. During this seminar, I will show the current status of the platform, and how we integrated the first three components highlighting the need of interdisciplinary teams to provide successful tools and approaches for complex heterogenous diseases.